Related Experiment Video
Updated: Apr 29, 2026
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter
Hiroki Endo1, Eiji Sakai1, Leo Taniguchi2
1Division of Gastroenterology, Yokohama City University School of Medicine, Yokohama, Japan.
Background:
To develop appropriate management strategies for patients who take low-dose aspirin, it is important to identify the risk factors for GI injury. However, few studies have described the risk factors for small-bowel injury in these patients.
Objective:
To investigate factors influencing the risk of small-bowel mucosal breaks in individuals taking continuous low-dose aspirin.
Design:
Capsule endoscopy data were collected prospectively from 5 institutions.
Setting:
Yokohama City University Hospital and 4 other hospitals.
Patients:
A total of 205 patients receiving treatment with low-dose aspirin for over 3 months.
Interventions:
Colonoscopic and upper GI endoscopy had been performed in all of the patients before the capsule endoscope evaluation.
Main Outcome Measurements:
Risk factors for small-bowel mucosal breaks.
Results:
Of the 198 patients (141 male; mean age 71.9 years) included in the final analysis, 114 (57.6%) had at least 1 mucosal break. Multivariate analysis identified protein pump inhibitor (PPI) use (OR 2.04; 95% confidence interval [CI], 1.05-3.97) and use of enteric-coated aspirin (OR 4.05; 95% CI, 1.49-11.0) as independent risk factors for the presence of mucosal breaks.
Limitations:
Cross-sectional study.
Conclusion:
PPI use appears to increase the risk of small-bowel injury in patients who take continuous low-dose aspirin. Clinicians should be aware of this effect of PPIs; new strategies are needed to treat aspirin-induced gastroenteropathy.
More Related Videos
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
01:25Peptic Ulcer Disease I: Introduction
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:24Peptic Ulcer Disease II: Pathophysiology
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...